Faricimab

Brand names: Vabysmo · Active ingredient: Faricimab

In short: VABYSMO is a vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2) inhibitor indicated for the treatment of patients with:

Forms & strengthsVABYSMO is a clear to opalescent, colorless to brownish-yellow solution available as: Injection: 6 mg (0.05 mL of 120 mg/mL solution) in a single-dose prefilled glass syringe Injection: 6 mg (0.05 mL of 120 mg/mL solution) in a single-dose glass vial
LabelGenentech, Inc.
Label updatedApr 22, 2026

What is Faricimab used for?

VABYSMO is a vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2) inhibitor indicated for the treatment of patients with:

Faricimab dosage

For intravitreal injection. VABYSMO must be administered by a qualified physician.

VABYSMO is available as:

Prefilled syringe: A sterile injection filter needle (30-gauge × ½-inch, Extra Thin Wall) with an integrated filter in the hub is provided. Each prefilled syringe should only be used for the treatment of a single eye.

Vial: A sterile 5-micron, blunt transfer filter needle (18-gauge × 1½-inch) is provided. Each vial should only be used for the treatment of a single eye.

The recommended dose for VABYSMO is 6 mg (0.05 mL of 120 mg/mL solution) administered by intravitreal injection every 4 weeks (approximately every 28 ± 7 days, monthly) for the first 4 doses, followed by optical coherence tomography and visual acuity evaluations 8 and 12 weeks later to inform whether to give a 6 mg dose via intravitreal injection on one of the following three regimens: 1) Weeks 28 and 44; 2) Weeks 24, 36 and 48; or 3) Weeks 20, 28, 36 and 44. Although additional efficacy was not demonstrated in most patients when VABYSMO was dosed every 4 weeks compared to every 8 weeks, some patients may need every 4 week (monthly) dosing after the first 4 doses. Patients should be assessed regularly.

VABYSMO is recommended to be dosed by following one of these two dose regimens: 1) 6 mg (0.05 mL of 120 mg/mL solution) administered by intravitreal injection every 4 weeks (approximately every 28 days ± 7 days, monthly) for at least 4 doses. If after at least 4 doses, resolution of edema based on the central subfield thickness (CST) of the macula as measured by optical coherence tomography is achieved, then the interval of dosing may be modified by extensions of up to 4 week interval increments or reductions of up to 8 week interval increments based on CST and visual acuity evaluations; or 2) 6 mg dose of VABYSMO can be administered every 4 weeks for the first 6 doses, followed by 6 mg dose via intravitreal injection at intervals of every 8 weeks (2 months). Although additional efficacy was not demonstrated in most patients when VABYSMO was dosed every 4 weeks compared to every 8 weeks, some patients may need every 4 week (monthly) dosing after the first 4 doses. Patients should be assessed regularly.

The recommended dose for VABYSMO is 6 mg (0.05 mL of 120 mg/mL solution) administered by intravitreal injection every 4 weeks (approximately every 28 ± 7 days, monthly).

In clinical studies, patients received monthly injections of VABYSMO for 6 months .

Before you start

Read all the instructions carefully before using VABYSMO.

The VABYSMO carton includes:

A sterile prefilled syringe in a sealed tray. The prefilled syringe is for treatment of a single eye.

A sterile injection filter needle (30-gauge × ½ inch, Extra Thin Wall) with an integrated filter in the hub. …

How to take Faricimab — instructions & advice from the label

Advise patients that in the days following VABYSMO administration, patients are at risk of developing endophthalmitis, retinal detachment, intraocular inflammation and retinal vasculitis with or without retinal vascular occlusion. If the eye becomes red, sensitive to light, painful, or develops a change in vision, advise the patient to seek immediate care from an ophthalmologist .

Patients may experience temporary visual disturbances after an intravitreal injection with VABYSMO and the associated eye examinations . Advise patients not to drive or use machinery until visual function has recovered sufficiently.

Warnings & precautions

Do not take this medicine if: VABYSMO is contraindicated in patients with ocular or periocular infections.

VABYSMO is contraindicated in patients with active intraocular inflammation.

VABYSMO is contraindicated in patients with known hypersensitivity to faricimab or any of the excipients in VABYSMO. Hypersensitivity reactions may manifest as rash, pruritus, urticaria, erythema, or severe intraocular inflammation.

Intravitreal injections, including Vabysmo, have been associated with endophthalmitis and retinal detachments . Proper aseptic injection techniques must always be used when administering VABYSMO. Patients should be instructed to report any signs or symptoms suggestive of endophthalmitis or retinal detachment without delay, to permit prompt and appropriate management .

Transient increases in intraocular pressure (IOP) have been seen within 60 minutes of intravitreal injection, including with VABYSMO . IOP and the perfusion of the optic nerve head should be monitored and managed appropriately .

Although there was a low rate of arterial thromboembolic events (ATEs) observed in the VABYSMO clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause).

The incidence of reported ATEs in the nAMD studies during the first year was 1% (7 out of 664) in patients treated with VABYSMO compared with 1% (6 out of 662) in patients treated with aflibercept .

The incidence of reported ATEs in the DME studies from baseline to week 100 was 5% (64 out of 1,262) in patients treated with VABYSMO compared with 5% (32 out of 625) in patients treated with aflibercept . …

Faricimab side effects

The following potentially serious adverse reactions are described elsewhere in the labeling:

Hypersensitivity

Endophthalmitis and retinal detachments

Increase in intraocular pressure

Thromboembolic events

Retinal Vasculitis and/or Retinal Vascular Occlusion

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in other clinical trials of the same or another drug and may not reflect the rates observed in practice.

The data described below reflect exposure to VABYSMO in 2,567 patients, which constituted the safety population in six Phase 3 studies .

Adverse Reactions | VABYSMO | Active Control (aflibercept)

AMDN=664 | DMEN=1,262 | RVON=641 | AMDN=662 | DMEN=625 | RVON=635

Cataract | 3% | 15% | < 1% | 2% | 12% | 1%

Conjunctival hemorrhage | 7% | 8% | 3% | 8% | 7% | 4%

Vitreous detachment | 3% | 5% | 2% | 3% | 4% | 2%

Vitreous floaters | 3% | 4% | 2% | 2% | 3% | 2%

Retinal pigment epithelial tearAMD only | 3% | 1%

Intraocular pressure increased | 3% | 4% | 1% | 2% | 3% | 3%

Eye pain | 3% | 3% | < 1% | 3% | 3% | < 1%

Intraocular inflammationIncluding iridocyclitis, iritis, uveitis, vitritis | 2% | 1% | 1% | 1% | 1% | < 1%

Eye irritation | 1% | < 1% | < 1% | < 1% | 1% | < 1%

Lacrimation increased | 1% | 1% | 0 | 1% | < 1% | < 1%

Ocular discomfort | 1% | 1% | < 1% | < 1% | < 1% | < 1%

Less common adverse reactions reported in < 1% of the patients treated with …

About this medicine

Faricimab-svoa is a humanized bispecific immunoglobulin G1 (IgG1) antibody that binds both vascular endothelial growth factor A (VEGF-A) and angiopoietin-2 (Ang-2). The fragment crystallizable (Fc) region of faricimab was engineered by selected point mutations to abolish binding interactions with Fcγ and FcRn receptors. Faricimab-svoa has a total molecular weight of approximately 149 kDa and is produced by recombinant DNA technology using mammalian Chinese Hamster Ovary (CHO) cell culture.

VABYSMO (faricimab-svoa) injection is a sterile, clear to opalescent, colorless to brownish-yellow solution in a single-dose prefilled glass syringe or glass vial for intravitreal administration. Each single-dose prefilled syringe or single-dose vial is designed to deliver 0.05 mL (50 microliters) of solution containing 6 mg faricimab-svoa, L-histidine (155 mcg), L-methionine (52.2 mcg), polysorbate 20 (20 mcg), sodium chloride (73.1 mcg), D-sucrose (2.74 mg) and Water for Injection, adjusted to pH 5.5 with acetic acid. The product does not contain an anti-microbial preservative. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 04cc9ef7-c02a-4e92-a655-0062674e8487. Read the full official label on DailyMed.